Aflibercept is an anti-angiogenic agent targeting vascular endothelial growth factor (VEGF), currently being developed by New York-based Regeneron in collaboration with Sanofi-Aventis. These two trials will be double-blind and placebo-controlled.
Sanofi-aventis will provide an update of the broad-based clinical development program planned for aflibercept, and additional details on these two trials, at its R&D day meeting scheduled to be held in Paris, France on September 17, 2007.